Charles River Laboratories International, Inc. (CRL): EPS (Basic)
-$2.91
Year ended 2025-12-27
| Period ended | EPS (Basic) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-27 | -$2.91 | n/m | 2026-02-18, From 2024-12-29 |
| 2024-12-28 | $0.20 | -97.8% | 2026-02-18, From 2023-12-31 |
| 2023-12-30 | $9.27 | -3.1% | 2026-02-18, From 2023-01-01 |
| 2022-12-31 | $9.57 | +23.2% | 2025-02-19, From 2021-12-26 |
| 2021-12-25 | $7.77 | +5.7% | 2024-02-14, From 2020-12-27 |
| 2020-12-26 | $7.35 | +42.2% | 2023-02-22, From 2019-12-29 |
| 2019-12-28 | $5.17 | +9.5% | 2022-02-16, From 2018-12-30 |
| 2018-12-29 | $4.72 | +81.5% | 2021-02-17, From 2017-12-31 |
| 2017-12-30 | $2.60 | -21.0% | 2020-02-11, From 2017-01-01 |
| 2016-12-31 | $3.29 | +2.5% | 2019-02-13, From 2015-12-27 |
| 2015-12-26 | $3.21 | +18.0% | 2018-02-13, From 2014-12-28 |
| 2014-12-27 | $2.72 | +26.5% | 2017-02-14, From 2013-12-29 |
| 2013-12-28 | $2.15 | +5.9% | 2016-02-12, From 2012-12-30 |
| 2012-12-29 | $2.03 | -6.0% | 2015-02-17, From 2012-01-01 |
| 2011-12-31 | $2.16 | n/m | 2014-02-25, From 2010-12-26 |
| 2010-12-25 | -$5.38 | n/m | 2013-02-27, From 2009-12-27 |
| 2009-12-26 | $1.75 | n/m | 2012-02-27, From 2008-12-28 |
| 2008-12-27 | -$7.80 | n/a | 2011-02-23, From 2007-12-30 |
EPS (Basic) at similar companies
| Company | Year ended | EPS (Basic) | Change YoY |
|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | -$2.91 | n/m |
| Incyte Corp (INCY) | 2025-12-31 | $6.59 | n/m |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $15.64 | +19.8% |
| Icon PLC (ICLR) | 2025-12-31 | $2.92 | -67.4% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $7.91 | +4.5% |
| NRC Health (NRC) | 2025-12-31 | $50.00 | n/m |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | -$0.42 | n/m |
| OmniAb, Inc. (OABI) | 2025-12-31 | -$0.57 | n/m |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | -$8.66 | n/m |
Compare CRL, INCY, MEDP, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗